• Explore /
  • Poster
  • / GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML.

GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML.

Abstract Poster

Authors

Daniel DeAngelo

Daniel J. DeAngelo

Dana-Farber Cancer Institute, Boston, MA

Daniel J. DeAngelo , Brian Andrew Jonas , Pamela S. Becker , Michael O'Dwyer , Anjali S. Advani , Paula Marlton , John Magnani , Helen M. Thackray , Jane Liesveld

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Other Novel Agents

Clinical Trial Registration Number

NCT02306291

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2560)

DOI

10.1200/JCO.2017.35.15_suppl.2560

Abstract #

2560

Poster Bd #

52

Abstract Disclosures

Similar Posters

First Author: Joseph G. Jurcic

First Author: Varada Salimath

First Author: Prajwal Boddu

First Author: Dinu Stefan